EPAS1 and hepatocellular carcinoma: One study reported that sorafenib, a multikinase inhibitor, switches from HIF-1α- to HIF-2α-dependent pathways, resulting in resistance to sorafenib in hypoxic hepatocellular carcinoma (HCC) by activating the TGF-α/EGFR pathway [22].